登录

Gyros Protein Technologies推出Gyrolab通用啮齿动物ADA试剂盒试剂,支持临床前免疫原性评估

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

businesswire | 2024-05-02 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


UPPSALA, Sweden--(BUSINESS WIRE)--Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

瑞典乌普萨拉--(商业新闻短讯)--Gyros Protein Technologies AB是自动化纳升级免疫测定的先驱,也是肽合成仪和试剂的领先供应商,今天宣布推出Gyrolab®通用啮齿动物抗药物抗体(ADA)试剂盒试剂,用于检测人IgG与啮齿动物抗人IgG的循环免疫复合物。

Validated for use with mouse and rat samples, the Kit Reagents provide a ready-to-use solution to accelerate screening of biotherapeutic drug candidates during preclinical development, enabling immunogenicity assessment of drug candidates without the need for drug-specific ADA assay development..

经验证可用于小鼠和大鼠样品,试剂盒试剂提供了一种即用解决方案,可在临床前开发过程中加速筛选生物治疗候选药物,从而无需药物特异性ADA分析开发即可对候选药物进行免疫原性评估。。

The new Kit Reagents expedite bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited..

新试剂盒试剂通过消除对分子间测定开发和优化的需求来加速生物分析,从而从纳升样品体积中提供稳健,可重复,可靠的数据。当在样本量可能有限的临床前动物模型中评估ADA评估时,这是有益的。。

Monitoring of ADAs is essential in preclinical studies. Multiple drug candidates are often evaluated in parallel using a small number of animals to provide understanding of clearance profiles and safety or efficacy issues resulting from immune complex formation. The Gyrolab Generic Rodent ADA Kit fills an industry-wide need for a generic assay solution to expedite immunogenicity assessment..

ADA的监测在临床前研究中至关重要。通常使用少量动物并行评估多种候选药物,以了解清除概况以及由免疫复合物形成引起的安全性或有效性问题。Gyrolab通用啮齿动物ADA试剂盒满足了业界对通用检测解决方案的需求,以加速免疫原性评估。。

The new bioanalysis kit is optimized for use on all Gyrolab systems and complements the Company’s existing portfolio of ready-to-use kits and solutions for pharmacokinetics and toxicokinetics. Following the introduction of Gyrolab Generic Cyno ADA Kit Reagents, the Gyrolab Generic Rodent ADA Kit Reagents further expand the utility of the Gyrolab platform into earlier drug screening and preclinical phases of development.

新的生物分析试剂盒针对所有Gyrolab系统进行了优化,补充了该公司现有的现成试剂盒和药代动力学和毒代动力学解决方案组合。在引入Gyrolab通用Cyno ADA试剂盒试剂后,Gyrolab通用啮齿动物ADA试剂盒试剂进一步将Gyrolab平台的实用性扩展到早期药物筛选和临床前开发阶段。

Automation with Gyrolab systems reduces variability due to manual pipetting and speeds up workflows by generating 96 data points within 80 minutes, helping to accelerate the development of novel human IgG therapeutics. Additionally, the Gyrolab platform supports the development of drug-specific ADA assays in the later stages of drug development, using automated acid dissociation in the Gyrolab Mixing CD 96 and the dedicated Gyrolab ADA Software, enabling immunogenicity assessment all the way from discovery through every phase of clinical analysis..

Gyrolab系统的自动化减少了手动移液的可变性,并通过在80分钟内生成96个数据点来加速工作流程,有助于加速新型人类IgG治疗剂的开发。此外,Gyrolab平台支持在药物开发的后期阶段开发药物特异性ADA分析,使用Gyrolab Mixing CD 96中的自动酸解离和专用Gyrolab ADA软件,从发现到临床分析的每个阶段都可以进行免疫原性评估。。

Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our portfolio enhances our offering of ready-to-use kits and solutions for use in drug screening and preclinical development.

Gyros Protein Technologies生物制药开发部总经理Mark Vossenaar评论道:“在我们的产品组合中添加Gyrolab通用啮齿动物ADA试剂盒试剂增强了我们提供的即用试剂盒和解决方案,可用于药物筛选和临床前开发。

Complementing our existing kits such as the Gyrolab Generic Cyno ADA Kit Reagents for use in non-human primates and our extensive offering in the pharmacokinetic and toxicokinetic bioanalysis space, our open Gyrolab platform provides a powerful tool to accelerate immunogenicity assessment at the preclinical stage.'.

作为对我们现有试剂盒的补充,例如用于非人灵长类动物的Gyrolab通用Cyno-ADA试剂盒试剂以及我们在药代动力学和毒代动力学生物分析领域的广泛产品,我们的开放Gyrolab平台提供了一个强大的工具来加速临床前阶段的免疫原性评估。”。

For more information: https://www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-rodent-ada-kit-reagents

有关更多信息:https://www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-rodent-ada-kit-reagents

推荐阅读

民生证券:医药行业专题研究——海外CXO板块2022年&2023年Q1回顾

动脉网APP 2023-07-06 09:22

民生证券:医药行业专题研究——海外CXO板块2022年&2023年Q1回顾

动脉网APP 2023-07-03 09:04

Mesa Laboratories收购Gyros Protein Technologies,基于蛋白技术推动药物发现与研发

Mailman 2019-11-12 14:52

businesswire

6557篇

最近内容 查看更多

Marinus Pharmaceuticals宣布结节性硬化综合征项目的关键业务更新

6 小时后

医疗保健服务提供商NADclinic和邦泰克生物工程宣布建立战略合作伙伴关系,通过NAD+的力量推动全球健康事业的未来发展

4 小时后

Drug Farm宣布美国食品药品监督管理局批准IND,使ROSAH综合征患者能够启动ALPK1选择性激酶抑制剂DF-003的1b期启动

4 小时后

相关公司查看更多

Gyros Protein Technologies

肽合成和生物分析解决方案供应商

立即沟通

产业链接查看更多